查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046095

被忽視的熱帶疾病診斷市場－全球產業規模、佔有率、趨勢、機會和預測：按疾病、診斷方法、服務類型、最終用途、地區和競爭對手分類，2021-2031年

Neglected Tropical Diseases Diagnosis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease, By Diagnostic Method, By Service Type, By End Use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球被忽視的熱帶疾病診斷市場預計將從 2025 年的 62.8 億美元成長到 2031 年的 80.1 億美元，複合年成長率為 4.14%，其主要透過提供快速診斷測試、分子測試和顯微鏡解決方案等專業診斷技術，在資源匱乏的環境中識別寄生蟲、病毒和細菌病原體。

這項成長主要得益於世界衛生組織（世衛組織）2030年消除疾病藍圖、加強官民合作關係以改善醫療衛生基礎設施，以及將定期篩檢納入國家全民健康覆蓋（UHC）。大量的國際和慈善支持對於資助開發和推廣價格合理、性能卓越的診斷工具也至關重要。同時，強而有力的政府主導的疾病根除計畫需要廣泛的監測和確認檢測來檢驗疾病的根除情況。鑑於2023年全球約有14.95億人需要干預以應對被忽視的熱帶疾病，這些努力至關重要。這凸顯了診斷能力對於應對影響5億人（包括5億兒童）的巨大疾病負擔的迫切需求。然而，阻礙市場擴張的一個主要挑戰是流行地區診斷項目的財務永續性。該領域高度依賴外部捐助資金，而非穩定的商業收入，導致資金週期不穩定且難以預測。這種波動性意味著需求往往受國際援助而非實際臨床需求所驅動，阻礙了製造商擴大生產規模，也妨礙了對分銷網路的長期投資。鑑於2018年至2023年間，官方發展援助（ODA）用於被忽視的熱帶疾病的資金減少了41%，這種經濟依賴性尤其令人擔憂。因此，受影響國家的國內衛生預算難以彌補資金缺口，阻礙了基本診斷工具的廣泛應用。然而，市場正湧現變革性趨勢。例如，將人工智慧（AI）整合到顯微鏡自動化系統中。這透過自動檢測寄生蟲病原體解決了熟練診斷人員短缺的問題，顯著減少了人為錯誤，並提高了診斷處理能力。同時，多重橫向流動化驗的普及使得在臨床環境中同時檢測多種被忽視的熱帶疾病成為可能，提供了一種至關重要的分散式篩檢功能，無需依賴遠端實驗室即可即時做出治療決策。這項轉變也體現在以下事實中：2024 年採購了超過一百萬個針對五種特定被忽視的熱帶疾病 (NTD) 的診斷檢測套組。

市場概覽
預測期 2027-2031
市場規模：2025年 62.8億美元
市場規模：2031年 80.1億美元
複合年成長率：2026-2031年 4.14%
成長最快的細分市場 醫院和診所
最大的市場 北美洲

市場促進因素

擴大國際資金和慈善支持對於加速全球被忽視的熱帶疾病診斷市場成長至關重要，這將有助於解決研發資金短缺問題。資金流入將促進開發適用於資源匱乏環境的經濟實惠、高效能的診斷工具，並支持擴大生產能力。例如，2025年10月，全球被忽視的熱帶疾病診斷技術基金會（GHIT Foundation）撥款約1,160萬美元，用於加強其結核病和被忽視的熱帶病產品開發平臺。這將降低開發新診斷方法的風險，並確保檢測解決方案能夠惠及偏遠社區，因為僅靠市場力量無法為這些社區提供足夠的創新獎勵。此外，各國政府主導的強力的舉措和疾病根除計劃正在顯著推動市場擴張，各國都在積極響應世界衛生組織（WHO）的《2030年藍圖》 。這些國家主導​​需要廣泛的監測和確認性檢測來檢驗疾病根除情況，這反過來又直接推動了快速和分子診斷試劑的購買。截至2025年1月，已有54個國家成功根除了至少一種被忽視的熱帶疾病，證明了這些嚴格的「檢測和治療」策略的有效性。然而，維持永續的診斷系統仍然至關重要。特別是，根據2025年6月的數據顯示，全球仍有5億兒童受到被忽視的熱帶疾病的影響，因此，對兒童專用診斷解決方案的需求依然迫切，以支持根除工作。

市場挑戰

流行地區診斷計畫的財務永續性是全球被忽視的熱帶疾病診斷市場成長的一大障礙。該行業嚴重依賴外部捐助者的資金，而非穩定的商業收入，導致採購週期往往不規則且難以預測。這種波動性阻礙了製造商擴大生產規模的能力，也妨礙了對分銷網路的長期投資，因為需求往往取決於國際援助的到位情況，而非實際的臨床需求。捐助者優先事項的轉變或全球預算的縮減會立即導致資源匱乏地區檢測活動的短缺，從而破壞疾病監測的連續性。在全球衛生資金近期縮減的情況下，這種經濟依賴性尤為嚴重。具體而言，2018年至2023年間，專門用於被忽視的熱帶疾病的官方發展援助（ODA）下降了41%。外部支持的大幅減少暴露了市場的脆弱性，因為受影響國家有限的國內衛生預算往往不足以彌補資金缺口。因此，無法獲得穩定的資金籌措模式阻礙了基本診斷工具的廣泛應用，並直接限制了市場擴張的潛力。

市場趨勢

將人工智慧 (AI) 整合到顯微鏡自動化系統中正成為一種變革性趨勢，它透過自動檢測寄生蟲病原體，直接解決了流行地區熟練診斷人員嚴重短缺的問題。這項技術利用先進的演算法分析數位化檢體影像，顯著減少人為錯誤，並提高了血吸蟲病和土源性線蟲病等疾病的診斷處理能力。一個值得關注的合作項目是“MultiplexAI 項目”，該項目由非洲和歐洲的九家機構組成的聯盟於 2025 年 9 月推出，旨在開發和檢驗適用於基層醫療機構的行動連線人工智慧工具。同時，多重橫向流動化驗的普及使得在臨床環境中同時檢測多種被忽視的熱帶疾病成為可能。這些先進的快速檢測方法在分散式篩檢模式中至關重要，使醫護人員無需依賴遠端檢測機構即可立即做出治療決策。這種營運轉變的規模是巨大的，世界衛生組織（世衛組織）支持在 2024 年採購超過一百萬份針對五種已確定的被忽視的熱帶病（NTD）的診斷測試，就是一個很好的例子。這反映出人們越來越依賴多功能、快速的診斷方法來幫助控制偏遠社區的感染傳播。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：被忽視的熱帶疾病診斷的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 疾病類型（登革熱、屈公病、狂犬病、布爾利氏潰瘍、亞烏茲氏病、淋巴絲蟲病、絛蟲病/囊蟲病、麥地那龍線蟲病、其他）
    • 診斷方法（傳統方法、分子/現代方法）
    • 服務類型（集中式服務、POC 服務）
    • 按應用領域（臨床檢查室、醫院/診所、家庭醫療保健）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美被忽視的熱帶疾病診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：被忽視的熱帶疾病診斷市場展望（歐洲）

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區被忽視的熱帶疾病診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：被忽視的熱帶疾病診斷市場展望－中東和非洲

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：被忽視的熱帶疾病診斷市場展望－南美洲

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：被忽視的全球熱帶疾病診斷市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • F. Hoffmann-La Roche Ltd
  • Abbott Laboratories Ltd.
  • Thermo Fisher Scientific Inc.
  • ZeptoMetrix LLC
  • InBios International, Inc.
  • DiaSys Diagnostics Systems GmbH
  • Genome Diagnostics Pvt. Ltd.
  • Omega Diagnostics Group Plc
  • Oscar Medicare Pvt Ltd.
  • Coris BioConcept

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 18735

The Global Neglected Tropical Diseases Diagnosis Market is anticipated to grow from USD 6.28 Billion in 2025 to USD 8.01 Billion by 2031, demonstrating a 4.14% CAGR, as it delivers specialized diagnostic technologies like rapid diagnostic tests, molecular assays, and microscopy solutions for identifying parasitic, viral, and bacterial pathogens in low-resource settings. This expansion is primarily driven by the World Health Organization's 2030 Roadmap for disease elimination and strengthened public-private partnerships improving healthcare infrastructure, along with the integration of routine screening into national universal health coverage. Significant international funding and philanthropic support are also crucial, providing capital for affordable, high-performance diagnostic tool development and manufacturing scale-up, while robust government initiatives and disease elimination programs necessitate widespread surveillance and confirmation testing to validate disease clearance. These efforts are vital given that approximately 1.495 billion people globally required interventions against neglected tropical diseases in 2023, highlighting the critical need for diagnostic capabilities to manage this substantial disease burden affecting populations, including half a billion children. A critical challenge impeding market expansion, however, is the financial sustainability of diagnostic programs in endemic regions. The sector's substantial reliance on external donor funding, rather than consistent commercial revenue, leads to irregular and unpredictable procurement cycles. This volatility prevents manufacturers from scaling production and discourages long-term investment in distribution networks, as demand is often dictated by available international aid rather than actual clinical necessity. Such economic dependence is particularly concerning given the recent 41% decrease in official development assistance for neglected tropical diseases between 2018 and 2023, leaving domestic health budgets in affected nations struggling to bridge the capital gap and thereby stalling the broader deployment of essential diagnostic tools. Nevertheless, the market is experiencing transformative trends such as the integration of Artificial Intelligence in microscopy automation, which addresses the shortage of skilled diagnosticians by automating parasitic pathogen detection, significantly reducing manual error and increasing diagnostic throughput. Simultaneously, the widespread adoption of multiplex lateral flow assays facilitates the concurrent detection of multiple neglected tropical diseases at the point of care, providing vital decentralized screening capabilities that enable immediate treatment decisions without relying on distant laboratory infrastructure, a shift highlighted by the procurement of over 1 million such diagnostic tests for five specific NTDs in 2024.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 6.28 Billion
Market Size 2031USD 8.01 Billion
CAGR 2026-20314.14%
Fastest Growing SegmentHospital/Clinics
Largest MarketNorth America

Market Driver

Growing international funding and philanthropic support are pivotal in accelerating the Global Neglected Tropical Diseases Diagnosis Market by bridging financial gaps for research and development. This influx of capital facilitates the creation of affordable, high-performance diagnostic tools tailored for low-resource settings and supports the expansion of manufacturing capabilities. For instance, the GHIT Fund awarded approximately USD 11.6 million in October 2025 to strengthen product development pipelines for tuberculosis and neglected tropical diseases, de-risking novel diagnostic development and ensuring testing solutions reach remote communities where market forces alone may not incentivize innovation. Furthermore, robust government initiatives and disease elimination programs significantly propel market expansion as nations align with the World Health Organization's 2030 Roadmap. These state-led efforts demand widespread surveillance and confirmation testing to validate disease clearance, directly driving the procurement of rapid diagnostic tests and molecular assays. As of January 2025, 54 countries have successfully eliminated at least one neglected tropical disease, underscoring the effectiveness of these rigorous testing-and-treat strategies. However, sustained diagnostic vigilance remains crucial, especially since June 2025 data indicates that half a billion children globally are impacted by neglected tropical diseases, creating persistent demand for pediatric-adapted diagnostic solutions to maintain elimination gains.

Market Challenge

The financial sustainability of diagnostic programs in endemic regions represents a critical barrier impeding the growth of the Global Neglected Tropical Diseases Diagnosis Market. The sector's heavy reliance on external donor funding, rather than consistent commercial revenue, often leads to irregular and unpredictable procurement cycles. This volatility hinders manufacturers' ability to scale production and discourages long-term investment in distribution networks, as demand is frequently dictated by the availability of international aid rather than actual clinical necessity. When donor priorities shift or global budgets contract, testing initiatives in low-resource settings face immediate shortages, disrupting the continuity of disease monitoring. This economic dependence is particularly damaging given recent contractions in global health financing; official development assistance specifically for neglected tropical diseases decreased by 41% between 2018 and 2023. This substantial reduction in external support exposes the market's fragility, as limited domestic health budgets in affected nations are often unable to bridge the capital gap. Consequently, the inability to secure consistent funding models stalls the broader deployment of essential diagnostic tools, directly restricting the market's potential for expansion.

Market Trends

The integration of Artificial Intelligence (AI) in microscopy automation is emerging as a transformative trend, directly addressing the critical shortage of skilled diagnosticians in endemic regions by automating the detection of parasitic pathogens. This technology employs advanced algorithms to analyze digital sample images, significantly reducing manual error and increasing diagnostic throughput for diseases such as schistosomiasis and soil-transmitted helminthiasis. A notable collaborative effort, the MultiplexAI Project, launched by a consortium of nine African and European institutions in September 2025, aims to develop and validate these mobile-connected AI tools for primary care settings. Simultaneously, the widespread adoption of multiplex lateral flow assays is enabling the concurrent detection of multiple neglected tropical diseases at the point of care. These sophisticated rapid tests are vital for decentralized screening models, empowering healthcare workers to make immediate treatment decisions without relying on distant laboratory infrastructure. The scale of this operational shift is substantial, as highlighted by the World Health Organization, which facilitated the procurement of over 1 million diagnostic tests for five specific NTDs in 2024, reflecting the growing reliance on versatile rapid diagnostics to support transmission interruption in remote communities.

Key Market Players

  • F. Hoffmann-La Roche Ltd
  • Abbott Laboratories Ltd.
  • Thermo Fisher Scientific Inc.
  • ZeptoMetrix LLC
  • InBios International, Inc.
  • DiaSys Diagnostics Systems GmbH
  • Genome Diagnostics Pvt. Ltd.
  • Omega Diagnostics Group Plc
  • Oscar Medicare Pvt Ltd.
  • Coris BioConcept

Report Scope

In this report, the Global Neglected Tropical Diseases Diagnosis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Neglected Tropical Diseases Diagnosis Market, By Disease

  • Dengue
  • Chikungunya
  • Rabies
  • Buruli Ulcer
  • Yaws
  • Lymphatic Filariasis
  • Taeniasis/Cysticercosis
  • Dracunculiasis
  • others

Neglected Tropical Diseases Diagnosis Market, By Diagnostic Method

  • Conventional
  • Molecular/Modern

Neglected Tropical Diseases Diagnosis Market, By Service Type

  • Centralized Service
  • POC Service

Neglected Tropical Diseases Diagnosis Market, By End Use

  • Clinical Labs
  • Hospital/Clinics
  • Home Healthcare

Neglected Tropical Diseases Diagnosis Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Neglected Tropical Diseases Diagnosis Market.

Available Customizations:

Global Neglected Tropical Diseases Diagnosis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Neglected Tropical Diseases Diagnosis Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Disease (Dengue, Chikungunya, Rabies, Buruli Ulcer, Yaws, Lymphatic Filariasis, Taeniasis/Cysticercosis, Dracunculiasis, others)
    • 5.2.2. By Diagnostic Method (Conventional, Molecular/Modern)
    • 5.2.3. By Service Type (Centralized Service, POC Service)
    • 5.2.4. By End Use (Clinical Labs, Hospital/Clinics, Home Healthcare)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Neglected Tropical Diseases Diagnosis Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Disease
    • 6.2.2. By Diagnostic Method
    • 6.2.3. By Service Type
    • 6.2.4. By End Use
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Neglected Tropical Diseases Diagnosis Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Disease
        • 6.3.1.2.2. By Diagnostic Method
        • 6.3.1.2.3. By Service Type
        • 6.3.1.2.4. By End Use
    • 6.3.2. Canada Neglected Tropical Diseases Diagnosis Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Disease
        • 6.3.2.2.2. By Diagnostic Method
        • 6.3.2.2.3. By Service Type
        • 6.3.2.2.4. By End Use
    • 6.3.3. Mexico Neglected Tropical Diseases Diagnosis Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Disease
        • 6.3.3.2.2. By Diagnostic Method
        • 6.3.3.2.3. By Service Type
        • 6.3.3.2.4. By End Use

7. Europe Neglected Tropical Diseases Diagnosis Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Disease
    • 7.2.2. By Diagnostic Method
    • 7.2.3. By Service Type
    • 7.2.4. By End Use
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Neglected Tropical Diseases Diagnosis Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Disease
        • 7.3.1.2.2. By Diagnostic Method
        • 7.3.1.2.3. By Service Type
        • 7.3.1.2.4. By End Use
    • 7.3.2. France Neglected Tropical Diseases Diagnosis Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Disease
        • 7.3.2.2.2. By Diagnostic Method
        • 7.3.2.2.3. By Service Type
        • 7.3.2.2.4. By End Use
    • 7.3.3. United Kingdom Neglected Tropical Diseases Diagnosis Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Disease
        • 7.3.3.2.2. By Diagnostic Method
        • 7.3.3.2.3. By Service Type
        • 7.3.3.2.4. By End Use
    • 7.3.4. Italy Neglected Tropical Diseases Diagnosis Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Disease
        • 7.3.4.2.2. By Diagnostic Method
        • 7.3.4.2.3. By Service Type
        • 7.3.4.2.4. By End Use
    • 7.3.5. Spain Neglected Tropical Diseases Diagnosis Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Disease
        • 7.3.5.2.2. By Diagnostic Method
        • 7.3.5.2.3. By Service Type
        • 7.3.5.2.4. By End Use

8. Asia Pacific Neglected Tropical Diseases Diagnosis Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Disease
    • 8.2.2. By Diagnostic Method
    • 8.2.3. By Service Type
    • 8.2.4. By End Use
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Neglected Tropical Diseases Diagnosis Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Disease
        • 8.3.1.2.2. By Diagnostic Method
        • 8.3.1.2.3. By Service Type
        • 8.3.1.2.4. By End Use
    • 8.3.2. India Neglected Tropical Diseases Diagnosis Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Disease
        • 8.3.2.2.2. By Diagnostic Method
        • 8.3.2.2.3. By Service Type
        • 8.3.2.2.4. By End Use
    • 8.3.3. Japan Neglected Tropical Diseases Diagnosis Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Disease
        • 8.3.3.2.2. By Diagnostic Method
        • 8.3.3.2.3. By Service Type
        • 8.3.3.2.4. By End Use
    • 8.3.4. South Korea Neglected Tropical Diseases Diagnosis Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Disease
        • 8.3.4.2.2. By Diagnostic Method
        • 8.3.4.2.3. By Service Type
        • 8.3.4.2.4. By End Use
    • 8.3.5. Australia Neglected Tropical Diseases Diagnosis Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Disease
        • 8.3.5.2.2. By Diagnostic Method
        • 8.3.5.2.3. By Service Type
        • 8.3.5.2.4. By End Use

9. Middle East & Africa Neglected Tropical Diseases Diagnosis Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Disease
    • 9.2.2. By Diagnostic Method
    • 9.2.3. By Service Type
    • 9.2.4. By End Use
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Neglected Tropical Diseases Diagnosis Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Disease
        • 9.3.1.2.2. By Diagnostic Method
        • 9.3.1.2.3. By Service Type
        • 9.3.1.2.4. By End Use
    • 9.3.2. UAE Neglected Tropical Diseases Diagnosis Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Disease
        • 9.3.2.2.2. By Diagnostic Method
        • 9.3.2.2.3. By Service Type
        • 9.3.2.2.4. By End Use
    • 9.3.3. South Africa Neglected Tropical Diseases Diagnosis Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Disease
        • 9.3.3.2.2. By Diagnostic Method
        • 9.3.3.2.3. By Service Type
        • 9.3.3.2.4. By End Use

10. South America Neglected Tropical Diseases Diagnosis Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Disease
    • 10.2.2. By Diagnostic Method
    • 10.2.3. By Service Type
    • 10.2.4. By End Use
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Neglected Tropical Diseases Diagnosis Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Disease
        • 10.3.1.2.2. By Diagnostic Method
        • 10.3.1.2.3. By Service Type
        • 10.3.1.2.4. By End Use
    • 10.3.2. Colombia Neglected Tropical Diseases Diagnosis Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Disease
        • 10.3.2.2.2. By Diagnostic Method
        • 10.3.2.2.3. By Service Type
        • 10.3.2.2.4. By End Use
    • 10.3.3. Argentina Neglected Tropical Diseases Diagnosis Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Disease
        • 10.3.3.2.2. By Diagnostic Method
        • 10.3.3.2.3. By Service Type
        • 10.3.3.2.4. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Neglected Tropical Diseases Diagnosis Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. F. Hoffmann-La Roche Ltd
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Abbott Laboratories Ltd.
  • 15.3. Thermo Fisher Scientific Inc.
  • 15.4. ZeptoMetrix LLC
  • 15.5. InBios International, Inc.
  • 15.6. DiaSys Diagnostics Systems GmbH
  • 15.7. Genome Diagnostics Pvt. Ltd.
  • 15.8. Omega Diagnostics Group Plc
  • 15.9. Oscar Medicare Pvt Ltd.
  • 15.10. Coris BioConcept

16. Strategic Recommendations

17. About Us & Disclaimer